MSH|^~\&|SendAppName^2.16.840.1.114222.TBD^ISO|Sending-Facility^2.16.840.1.114222.TBD^ISO|PHINCDS^2.16.840.1.114222.4.3.2.10^ISO|PHIN^2.16.840.1.114222^ISO|20140630120030.1234-0500||ORU^R01^ORU_R01|MESSAGE CONTROL ID|D|2.5.1|||||||||NOTF_ORU_v3.0^PHINProfileID^2.16.840.1.114222.4.10.3^ISO~Generic_MMG_V2.0^PHINMsgMapID^2.16.840.1.114222.4.10.4^ISO~TB_MMG_V3.0^PHINMsgMapID^2.16.840.1.114222.4.10.4^ISOPID|1||TB_TC_02^^^SendAppName&2.16.840.1.114222.nnnn&ISO||~^^^^^^S||20000101|F||2076-8^Native Hawaiian or Other Pacific Islander^CDCREC~2106-3^White^CDCREC|^^Atlanta^13^30313^^^^13121^13121009101|||||||||||2186-5^Not Hispanic or Latino^CDCREC||||||||||||||||OBR|1||TB_TC_02^SendAppName^2.16.840.1.114222.TBD^ISO|68991-9^Epidemiologic Information^LN|||20170201111111|||||||||||||||20180502111111|||C||||||10220^Tuberculosis^NNDOBX|1|CWE|78746-5^Country of Birth^LN||GBR^UNITED KINGDOM^ISO3166_1||||||FOBX|2|CWE|77983-5^Country of Usual Residence^LN||GBR^UNITED KINGDOM^ISO3166_1||||||FOBX|3|TS|11368-8^Date of Illness Onset^LN||20170115||||||FOBX|4|CWE|77978-5^Subject Died^LN||N^No^HL70136||||||FOBX|5|SN|77998-3^Age at Case Investigation^LN||^18|a^year [time]^UCUM|||||FOBX|6|CWE|77982-7^Case Disease Imported Code^LN||UNK^Unknown^NULLFL||||||FOBX|7|TS|77976-9^Illness End Date^LN||20180301||||||FOBX|8|SN|77977-7^Illness Duration^LN||^14|mo^month [time]^UCUM|||||FOBX|9|CWE|77996-7^Pregnancy Status^LN||N^No^HL70136||||||FOBX|10|ST|74549-7^Person Reporting to CDC - Name^LN||Skywalker, Luke||||||FOBX|11|ST|74547-1^Person Reporting to CDC - Email^LN||lskywalker@ga.dph.gov||||||FOBX|12|DT|77979-3^Case Investigation Start Date^LN||20170201||||||FOBX|13|DT|77995-9^Date Reported^LN||20170201||||||FOBX|14|TS|77972-8^Earliest Date Reported to County^LN||20170201||||||FOBX|15|CWE|77989-2^Transmission Mode^LN||416380006^Airborne transmission^SCT||||||FOBX|16|TS|77973-6^Earliest Date Reported to State^LN||20170201||||||FOBX|17|SN|77991-8^MMWR Week^LN||^10||||||FOBX|18|DT|77992-6^MMWR Year^LN||2017||||||FOBX|19|CWE|77966-0^Reporting State^LN||13^Georgia^FIPS5_2||||||FOBX|20|CWE|77967-8^Reporting County^LN||13121^Fulton, GA^FIPS6_4||||||FOBX|21|CWE|77968-6^National Reporting Jurisdiction^LN||13^GA^FIPS5_2||||||FOBX|22|CWE|77990-0^Case Class Status Code^LN||410605003^Confirmed present^SCT||||||FOBX|23|CWE|77980-1^Case Outbreak Indicator^LN||N^No^HL70136||||||FOBX|24|ST|INV1107^TB State Case Number^PHINQUESTION||2017GA654987321||||||FOBX|25|CWE|DEM153^Detailed Race^PHINQUESTION||2078-4^Polynesian^CDCREC||||||FOBX|26|CWE|DEM2003^US Born^PHINQUESTION||N^No^HL70136||||||FOBX|27|CWE|INV1116^Initial Reason for Evaluation^PHINQUESTION||PHC680^TB Symptoms^CDCPHINVS||||||FOBX|28|ST|INV1108^City or County Case Number^PHINQUESTION||2017GAFULTON123||||||FOBX|29|CWE|76689-9^Birth Sex^LN||F^Female^HL70001||||||FOBX|30|CWE|INV1109^Previously Counted Case^PHINQUESTION||PHC660^Verified Case: TB treatment initiated in another country^CDCPHINVS||||||FOBX|31|ST|INV1110^Previously Reported State Case Number^PHINQUESTION||2017GBR873223||||||FOBX|32|CWE|INV1111^Country of Verified Case^PHINQUESTION||GBR^UNITED KINGDOM^ISO3166_1||||||FOBX|33|CWE|INV1112^Inside City Limits^PHINQUESTION||Y^Yes^HL70136||||||FOBX|34|CWE|INV1276^Occupation and Industry Category^PHINQUESTION||223366009^Healthcare worker^SCT||||||FOBX|35|ST|85658-3^Current Occupation^LN|1|Receptionist||||||FOBX|36|CE|85659-1^Current Occupation Standardized^LN|1|5400^Receptionists and information clerks [5400]^CDCOCCUPATION2010||||||FOBX|37|ST|85078-4^Current Industry^LN|1|Office of Physicians||||||FOBX|38|CE|85657-5^Current Industry Standardized^LN|1|7970^Offices of physicians [7970]^CDCINDUSTRY2010||||||FOBX|39|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|2|PHC2098^Diabetic at Diagnostic Evaluation^CDCPHINVS||||||FOBX|40|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|2|Y^Yes^HL70136||||||FOBX|41|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|3|46177005^End-Stage Renal Disease^SCT||||||FOBX|42|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|3|N^No^HL70136||||||FOBX|43|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|4|86933000^Heavy Alcohol Use in the Past 12 Months^SCT||||||FOBX|44|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|4|N^No^HL70136||||||FOBX|45|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|5|161663000^Post-Organ Transplantation^SCT||||||FOBX|46|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|5|N^No^HL70136||||||FOBX|47|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|6|32911000^Homeless Ever^SCT||||||FOBX|48|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|6|N^No^HL70136||||||FOBX|49|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|7|PHC1876^Homeless in the Past 12 Months^CDCPHINVS||||||FOBX|50|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|7|N^No^HL70136||||||FOBX|51|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|8|226034001^Injecting Drug Use in the Past 12 Months^SCT||||||FOBX|52|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|8|Y^Yes^HL70136||||||FOBX|53|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|9|PHC1877^Noninjecting Drug Use in the Past 12 Months^CDCPHINVS||||||FOBX|54|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|9|N^No^HL70136||||||FOBX|55|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|10|42665001^Resident of Long-Term Care Facility at Diagnositic Evaluation^SCT||||||FOBX|56|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|10|Y^Yes^HL70136||||||FOBX|57|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|11|OTH^Other (specify)^NULLFL||||||FOBX|58|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|11|N^No^HL70136||||||FOBX|59|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|12|257656006^Resident of Correctional Facility at Diagnostic Evaluation^SCT||||||FOBX|60|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|12|N^No^HL70136||||||FOBX|61|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|13|PHC2099^Resident of Correctional Facility Ever^CDCPHINVS||||||FOBX|62|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|13|N^No^HL70136||||||FOBX|63|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|14|PHC690^TNF Antagonist Therapy^CDCPHINVS||||||FOBX|64|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|14|N^No^HL70136||||||FOBX|65|CWE|INV1117^Patient Epidemiological Risk Factors^PHINQUESTION|15|3738000^Viral hepatitis (any type)^SCT||||||FOBX|66|CWE|INV1118^Patient Epidemiological Risk Factors Indicator^PHINQUESTION|15|Y^Yes^HL70136||||||FOBX|67|CWE|INV1120^Type of Long-Term Care Facility^PHINQUESTION||283Q00000X^Mental Health Facility^HCPT||||||FOBX|68|CWE|72166-2^Smoking Status^LN||8517006^Former smoker^SCT||||||FOBX|69|CWE|INV1121^Patient lived outside of US for more than 2 months^PHINQUESTION||Y^Yes^HL70136||||||FOBX|70|CWE|INV290^Test Type^PHINQUESTION|16|20431-3^Smear^LN||||||FOBX|71|CWE|INV291^Test Result^PHINQUESTION|16|10828004^Positive^SCT||||||FOBX|72|TS|82773-3^Date/Time of Lab Result^LN|16|20170206||||||FOBX|73|CWE|31208-2^Specimen Source Site^LN|16|119334006^sputum^SCT||||||FOBX|74|TS|68963-8^Specimen Collection Date/Time^LN|16|20170204||||||FOBX|75|CWE|INV290^Test Type^PHINQUESTION|17|20431-3^Smear^LN||||||FOBX|76|CWE|INV291^Test Result^PHINQUESTION|17|10828004^Positive^SCT||||||FOBX|77|TS|82773-3^Date/Time of Lab Result^LN|17|20170209||||||FOBX|78|CWE|31208-2^Specimen Source Site^LN|17|119334006^sputum^SCT||||||FOBX|79|TS|68963-8^Specimen Collection Date/Time^LN|17|20170207||||||FOBX|80|CWE|INV290^Test Type^PHINQUESTION|18|20431-3^Smear^LN||||||FOBX|81|CWE|INV291^Test Result^PHINQUESTION|18|10828004^Positive^SCT||||||FOBX|82|TS|82773-3^Date/Time of Lab Result^LN|18|20170309||||||FOBX|83|CWE|31208-2^Specimen Source Site^LN|18|119334006^sputum^SCT||||||FOBX|84|TS|68963-8^Specimen Collection Date/Time^LN|18|20170307||||||FOBX|85|CWE|INV290^Test Type^PHINQUESTION|19|20431-3^Smear^LN||||||FOBX|86|CWE|INV291^Test Result^PHINQUESTION|19|260385009^Negative^SCT||||||FOBX|87|TS|82773-3^Date/Time of Lab Result^LN|19|20180410||||||FOBX|88|CWE|31208-2^Specimen Source Site^LN|19|119334006^sputum^SCT||||||FOBX|89|TS|68963-8^Specimen Collection Date/Time^LN|19|20180407||||||FOBX|90|CWE|INV290^Test Type^PHINQUESTION|20|50595-8^Pathology^LN||||||FOBX|91|TS|82773-3^Date/Time of Lab Result^LN|20|20170210||||||FOBX|92|CWE|31208-2^Specimen Source Site^LN|20|110547006^Epiglottis and larynx, CS^SCT||||||FOBX|93|TS|68963-8^Specimen Collection Date/Time^LN|20|20170207||||||FOBX|94|CWE|INV290^Test Type^PHINQUESTION|21|LAB673^NAA^PHINQUESTION||||||FOBX|95|CWE|INV291^Test Result^PHINQUESTION|21|10828004^Positive^SCT||||||FOBX|96|TS|82773-3^Date/Time of Lab Result^LN|21|20170205||||||FOBX|97|TS|68963-8^Specimen Collection Date/Time^LN|21|20170204||||||FOBX|98|CWE|INV290^Test Type^PHINQUESTION|22|50941-4^Culture^LN||||||FOBX|99|CWE|INV291^Test Result^PHINQUESTION|22|10828004^Positive^SCT||||||FOBX|100|TS|82773-3^Date/Time of Lab Result^LN|22|20170310||||||FOBX|101|CWE|31208-2^Specimen Source Site^LN|22|119334006^sputum^SCT||||||FOBX|102|TS|68963-8^Specimen Collection Date/Time^LN|22|20170204||||||FOBX|103|CWE|INV290^Test Type^PHINQUESTION|23|50941-4^Culture^LN||||||FOBX|104|CWE|INV291^Test Result^PHINQUESTION|23|10828004^Positive^SCT||||||FOBX|105|TS|82773-3^Date/Time of Lab Result^LN|23|20170310||||||FOBX|106|CWE|31208-2^Specimen Source Site^LN|23|119334006^sputum^SCT||||||FOBX|107|TS|68963-8^Specimen Collection Date/Time^LN|23|20170207||||||FOBX|108|CWE|INV290^Test Type^PHINQUESTION|24|50941-4^Culture^LN||||||FOBX|109|CWE|INV291^Test Result^PHINQUESTION|24|10828004^Positive^SCT||||||FOBX|110|TS|82773-3^Date/Time of Lab Result^LN|24|20170417||||||FOBX|111|CWE|31208-2^Specimen Source Site^LN|24|119334006^sputum^SCT||||||FOBX|112|TS|68963-8^Specimen Collection Date/Time^LN|24|20170307||||||FOBX|113|CWE|INV290^Test Type^PHINQUESTION|25|50941-4^Culture^LN||||||FOBX|114|CWE|INV291^Test Result^PHINQUESTION|25|260385009^Negative^SCT||||||FOBX|115|TS|82773-3^Date/Time of Lab Result^LN|25|20180513||||||FOBX|116|CWE|31208-2^Specimen Source Site^LN|25|119334006^sputum^SCT||||||FOBX|117|TS|68963-8^Specimen Collection Date/Time^LN|25|20180307||||||FOBX|118|CWE|INV290^Test Type^PHINQUESTION|26|50941-4^Culture^LN||||||FOBX|119|CWE|INV291^Test Result^PHINQUESTION|26|10828004^Positive^SCT||||||FOBX|120|TS|82773-3^Date/Time of Lab Result^LN|26|20170315||||||FOBX|121|CWE|31208-2^Specimen Source Site^LN|26|110547006^Epiglottis and larynx, CS^SCT||||||FOBX|122|TS|68963-8^Specimen Collection Date/Time^LN|26|20170210||||||FOBX|123|CWE|INV290^Test Type^PHINQUESTION|27|TB119^Tuberculin Skin Test^PHINQUESTION||||||FOBX|124|CWE|INV291^Test Result^PHINQUESTION|27|10828004^Positive^SCT||||||FOBX|125|TS|82773-3^Date/Time of Lab Result^LN|27|20170204||||||FOBX|126|TS|68963-8^Specimen Collection Date/Time^LN|27|20170201||||||FOBX|127|ST|LAB628^Test Result Quantitative^PHINQUESTION|27|12||||||FOBX|128|CWE|LAB115^Result Units^PHINQUESTION|27|mm^millimeter^UCUM||||||FOBX|129|CWE|INV290^Test Type^PHINQUESTION|28|71773-6^IGRA-Unknown^LN||||||FOBX|130|CWE|INV291^Test Result^PHINQUESTION|28|385660001^Not Done^SCT||||||FOBX|131|CWE|INV290^Test Type^PHINQUESTION|29|55277-8^HIV Status^LN||||||FOBX|132|CWE|INV291^Test Result^PHINQUESTION|29|10828004^Positive^SCT||||||FOBX|133|TS|82773-3^Date/Time of Lab Result^LN|29|20170215||||||FOBX|134|CWE|31208-2^Specimen Source Site^LN|29|87612001^Blood^SCT||||||FOBX|135|TS|68963-8^Specimen Collection Date/Time^LN|29|20170210||||||FOBX|136|CWE|INV290^Test Type^PHINQUESTION|30|24467-3^CD4 Count^LN||||||FOBX|137|TS|82773-3^Date/Time of Lab Result^LN|30|20170215||||||FOBX|138|TS|68963-8^Specimen Collection Date/Time^LN|30|20170210||||||FOBX|139|ST|LAB628^Test Result Quantitative^PHINQUESTION|30|500||||||FOBX|140|CWE|LAB115^Result Units^PHINQUESTION|30|{cells}/uL^cells per microliter^UCUM||||||FOBX|141|CWE|INV290^Test Type^PHINQUESTION|31|76629-5^Fasting blood glucose^LN||||||FOBX|142|TS|82773-3^Date/Time of Lab Result^LN|31|20170214||||||FOBX|143|TS|68963-8^Specimen Collection Date/Time^LN|31|20170210||||||FOBX|144|ST|LAB628^Test Result Quantitative^PHINQUESTION|31|150||||||FOBX|145|CWE|LAB115^Result Units^PHINQUESTION|31|mg/dL^milligram per deciliter^UCUM||||||FOBX|146|CWE|LAB677^Type of Chest Study^PHINQUESTION|32|399208008^Plain Chest X-Ray^SCT||||||FOBX|147|CWE|LAB678^Result of Chest Study^PHINQUESTION|32|PHC1873^Consistent with TB^CDCPHINVS||||||FOBX|148|CWE|LAB679^Evidence of Cavity^PHINQUESTION|32|N^No^HL70136||||||FOBX|149|CWE|LAB680^Evidence of Miliary TB^PHINQUESTION|32|N^No^HL70136||||||FOBX|150|TS|LAB681^Date of Chest Study^PHINQUESTION|32|20170206||||||FOBX|151|CWE|LAB677^Type of Chest Study^PHINQUESTION|33|169069000^CT Scan^SCT||||||FOBX|152|CWE|LAB678^Result of Chest Study^PHINQUESTION|33|385660001^Not Done^SCT||||||FOBX|153|CWE|INV1274^Case Meets Binational Reporting Criteria^PHINQUESTION||N^No^HL70136||||||FOBX|154|CWE|INV1122^Identified During Contact Investigation^PHINQUESTION||Y^Yes^HL70136||||||FOBX|155|CWE|INV1123^Evaluation During Contact Investigation^PHINQUESTION||Y^Yes^HL70136||||||FOBX|156|ST|INV1124^Linked Case Number^PHINQUESTION||2017GA121212121||||||FOBX|157|DT|86948-7^Date Treatment or Therapy Started^PHINQUESTION||20170205||||||FOBX|158|CWE|55753-8^Treatment Administration Type^LN||435891000124101^DOT (Directly observed therapy, in person)^SCT~PHC1881^EDOT (Electronic DOT, via video call or other electronic method)^CDCPHINVS||||||FOBX|159|DT|63939-3^Date Treatment or Therapy Stopped^LN||20180301||||||FOBX|160|CWE|INV1115^Case Verification Category^PHINQUESTION||PHC654^3 - Clinical Case Definition^CDCPHINVS||||||FOBX|161|CWE|TB101^Status at Diagnosis of TB^PHINQUESTION||438949009^Alive^SCT||||||FOBX|162|CWE|INV1133^Site of Disease^PHINQUESTION||110547006^Epiglottis and larynx, CS^SCT||||||FOBX|163|CWE|INV1134^Contact Investigation^PHINQUESTION||Y^Yes^HL70136||||||FOBX|164|CWE|161413004^History of Previous Illness^SCT||Y^Yes^HL70136||||||FOBX|165|CWE|INV1135^Diagnosis Type^PHINQUESTION|34|56717001^TB^SCT||||||FOBX|166|DT|82758-4^Date of Previous Illness^LN|34|20100101||||||FOBX|167|ST|INV1136^Previous State Case Number^PHINQUESTION|34|2010FL876545678||||||FOBX|168|CWE|INV1137^Completed Treatment for Previous Diagnosis^PHINQUESTION|34|N^No^HL70136||||||FOBX|169|CWE|INV1135^Diagnosis Type^PHINQUESTION|35|11999007^LTBI^SCT||||||FOBX|170|DT|82758-4^Date of Previous Illness^LN|35|200801||||||FOBX|171|CWE|INV1137^Completed Treatment for Previous Diagnosis^PHINQUESTION|35|N^No^HL70136||||||FOBX|172|CWE|INV1139^Reason Not Treated with RIPE^PHINQUESTION||PHC1909^Suspected Drug Resistance^CDCPHINVS||||||FOBX|173|CWE|INV1140^Reason Therapy Stopped^PHINQUESTION||182992009^Completed Treatment^SCT||||||FOBX|174|CWE|INV1141^Reason Therapy Extended^PHINQUESTION||PHC700^Inability to Use Rifampin (Resistance, Intolerance, etc.)^CDCPHINVS||||||FOBX|175|CWE|INV1167^Final Disease Outcome^PHINQUESTION||N^No^HL70136||||||FOBX|176|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|36|641^Amikacin^RXNORM||||||FOBX|177|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|36|N^No^HL70136||||||FOBX|178|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|37|7833^Para-Aminesalicylicacid^RXNORM||||||FOBX|179|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|37|N^No^HL70136||||||FOBX|180|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|38|1364504^Bedaquiline^RXNORM||||||FOBX|181|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|38|N^No^HL70136||||||FOBX|182|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|39|78903^Capreomycin^RXNORM||||||FOBX|183|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|39|Y^Yes^HL70136||||||FOBX|184|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|40|2551^Ciprofloxacin^RXNORM||||||FOBX|185|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|40|N^No^HL70136||||||FOBX|186|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|41|2592^Clofazimine^RXNORM||||||FOBX|187|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|41|N^No^HL70136||||||FOBX|188|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|42|3007^Cycloserine^RXNORM||||||FOBX|189|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|42|N^No^HL70136||||||FOBX|190|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|43|PHC1889^Delamanid^CDCPHINVS||||||FOBX|191|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|43|N^No^HL70136||||||FOBX|192|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|44|4110^Ethambutol^RXNORM||||||FOBX|193|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|44|Y^Yes^HL70136||||||FOBX|194|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|45|4127^Ethionamide^RXNORM||||||FOBX|195|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|45|N^No^HL70136||||||FOBX|196|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|46|6038^Isoniazid^RXNORM||||||FOBX|197|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|46|Y^Yes^HL70136||||||FOBX|198|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|47|6099^Kanamycin^RXNORM||||||FOBX|199|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|47|N^No^HL70136||||||FOBX|200|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|48|82122^Levofloxacin^RXNORM||||||FOBX|201|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|48|N^No^HL70136||||||FOBX|202|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|49|190376^Linezolid^RXNORM||||||FOBX|203|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|49|N^No^HL70136||||||FOBX|204|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|50|139462^Moxifloxacin^RXNORM||||||FOBX|205|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|50|N^No^HL70136||||||FOBX|206|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|51|7623^Ofloxacin^RXNORM||||||FOBX|207|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|51|N^No^HL70136||||||FOBX|208|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|52|OTH^Other (specify)^NULLFL||||||FOBX|209|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|52|N^No^HL70136||||||FOBX|210|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|53|PHC1888^Other Quinolones^CDCPHINVS||||||FOBX|211|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|53|N^No^HL70136||||||FOBX|212|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|54|8987^Pyrazinamide^RXNORM||||||FOBX|213|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|54|N^No^HL70136||||||FOBX|214|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|55|55672^Rifabutin^RXNORM||||||FOBX|215|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|55|Y^Yes^HL70136||||||FOBX|216|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|56|9384^Rifampin^RXNORM||||||FOBX|217|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|56|Y^Yes^HL70136||||||FOBX|218|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|57|35617^Rifapentine^RXNORM||||||FOBX|219|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|57|N^No^HL70136||||||FOBX|220|CWE|INV1143^Initial Drug Regimen^PHINQUESTION|58|10109^Streptomycin^RXNORM||||||FOBX|221|CWE|INV1144^Initial Drug Regimen Indicator^PHINQUESTION|58|N^No^HL70136||||||FOBX|222|CWE|INV1145^Isolate Submitted for Genotyping^PHINQUESTION||Y^Yes^HL70136||||||FOBX|223|ST|INV1146^Accession Number for Genotyping^PHINQUESTION||17RF1000||||||FOBX|224|CWE|INV1147^Phenotypic Drug Susceptibility Completed^PHINQUESTION||Y^Yes^HL70136||||||FOBX|225|CWE|INV1148^Molecular Drug Susceptibility Completed^PHINQUESTION||Y^Yes^HL70136||||||FOBX|226|CWE|INV1275^Patient Treated as MDR Case^PHINQUESTION||Y^Yes^HL70136||||||FOBX|227|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|59|18860-7^Amikacin^LN||||||FOBX|228|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|59|385660001^Not done^SCT||||||FOBX|229|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|60|LAB675^Bedaquiline^PHINQUESTION||||||FOBX|230|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|60|385660001^Not done^SCT||||||FOBX|231|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|61|18872-2^Capreomycin^LN||||||FOBX|232|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|61|20170207||||||FOBX|233|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|61|20170512||||||FOBX|234|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|61|119334006^sputum^SCT||||||FOBX|235|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|61|131196009^Susceptible^SCT||||||FOBX|236|CWE|LABAST7^Antimicrobial Susceptibility Test Method^PHINQUESTION|61|88629000^Agar dilution/MIC^SCT||||||FOBX|237|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|62|18906-8^Ciprofloxacin^LN||||||FOBX|238|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|62|385660001^Not done^SCT||||||FOBX|239|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|63|23627-3^Clofazimine^LN||||||FOBX|240|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|63|UNK^Unknown^NULLFL||||||FOBX|241|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|64|18914-2^Cycloserine^LN||||||FOBX|242|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|64|385660001^Not done^SCT||||||FOBX|243|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|65|LAB676^Delamanid^PHINQUESTION||||||FOBX|244|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|65|385660001^Not done^SCT||||||FOBX|245|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|66|18921-7^Ethambutol^LN||||||FOBX|246|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|66|20170207||||||FOBX|247|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|66|20170512||||||FOBX|248|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|66|119334006^sputum^SCT||||||FOBX|249|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|66|30714006^Resistant^SCT||||||FOBX|250|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|67|18922-5^Ethionamide^LN||||||FOBX|251|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|67|385660001^Not done^SCT||||||FOBX|252|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|68|18934-0^Isoniazid^LN||||||FOBX|253|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|68|20170210||||||FOBX|254|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|68|20170512||||||FOBX|255|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|68|119334006^sputum^SCT||||||FOBX|256|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|68|30714006^Resistant^SCT||||||FOBX|257|CWE|LABAST7^Antimicrobial Susceptibility Test Method^PHINQUESTION|68|88629000^Agar dilution/MIC^SCT||||||FOBX|258|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|69|18935-7^Kanamycin^LN||||||FOBX|259|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|69|385660001^Not done^SCT||||||FOBX|260|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|70|18935-7^Kanamycin^LN||||||FOBX|261|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|70|20170210||||||FOBX|262|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|70|20170525||||||FOBX|263|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|70|119334006^sputum^SCT||||||FOBX|264|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|70|30714006^Resistant^SCT||||||FOBX|265|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|71|20629-2^Levofloxacin^LN||||||FOBX|266|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|71|UNK^Unknown^NULLFL||||||FOBX|267|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|72|29258-1^Linezolid^LN||||||FOBX|268|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|72|385660001^Not done^SCT||||||FOBX|269|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|73|31039-1^Moxifloxacin^LN||||||FOBX|270|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|73|385660001^Not done^SCT||||||FOBX|271|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|74|18959-7^Ofloxacin^LN||||||FOBX|272|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|74|20170210||||||FOBX|273|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|74|20170512||||||FOBX|274|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|74|119334006^sputum^SCT||||||FOBX|275|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|74|131196009^Susceptible^SCT||||||FOBX|276|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|75|LAB674^Other Quinolones^PHINQUESTION||||||FOBX|277|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|75|385660001^Not done^SCT||||||FOBX|278|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|76|23629-9^Para-Aminesalicylicacid^LN||||||FOBX|279|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|76|20170210||||||FOBX|280|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|76|20170512||||||FOBX|281|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|76|119334006^sputum^SCT||||||FOBX|282|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|76|131196009^Susceptible^SCT||||||FOBX|283|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|77|18973-8^Pyrazinamide^LN||||||FOBX|284|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|77|20170210||||||FOBX|285|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|77|20170512||||||FOBX|286|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|77|119334006^sputum^SCT||||||FOBX|287|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|77|131196009^Susceptible^SCT||||||FOBX|288|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|78|18973-8^Pyrazinamide^LN||||||FOBX|289|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|78|20170307||||||FOBX|290|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|78|20170622||||||FOBX|291|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|78|119334006^sputum^SCT||||||FOBX|292|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|78|30714006^Resistant^SCT||||||FOBX|293|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|79|19149-4^Rifabutin^LN||||||FOBX|294|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|79|20170210||||||FOBX|295|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|79|20170512||||||FOBX|296|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|79|119334006^sputum^SCT||||||FOBX|297|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|79|131196009^Susceptible^SCT||||||FOBX|298|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|80|18974-6^Rifampin^LN||||||FOBX|299|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|80|20170207||||||FOBX|300|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|80|20170522||||||FOBX|301|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|80|119334006^sputum^SCT||||||FOBX|302|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|80|30714006^Resistant^SCT||||||FOBX|303|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|81|76627-9^Rifapentine^LN||||||FOBX|304|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|81|385660001^Not done^SCT||||||FOBX|305|CWE|LABAST6^Antimicrobial Susceptibility Test Type^PHINQUESTION|82|18982-9^Streptomycin^LN||||||FOBX|306|DT|LABAST5^Antimicrobial Susceptibility Specimen Collection Date^PHINQUESTION|82|20170207||||||FOBX|307|DT|LABAST14^Antimicrobial Susceptibility Result Reported Date^PHINQUESTION|82|20170512||||||FOBX|308|CWE|LABAST3^Antimicrobial Susceptibility Specimen Type^PHINQUESTION|82|119334006^sputum^SCT||||||FOBX|309|CWE|LABAST8^Antimicrobial Susceptibility Test Interpretation^PHINQUESTION|82|30714006^Resistant^SCT||||||FOBX|310|CWE|48018-6^Gene Identifier^LN|83|PHC1894^rpoB^CDCPHINVS||||||FOBX|311|TS|LAB682^Molecular Susceptibility Specimen Collection Date^PHINQUESTION|83|20170207||||||FOBX|312|TS|LAB683^Molecular Susceptibility Date Reported^PHINQUESTION|83|20170208||||||FOBX|313|CWE|LAB684^Molecular Susceptibility Specimen Type^PHINQUESTION|83|119334006^sputum^SCT||||||FOBX|314|CWE|LAB685^Molecular Susceptibility Test Result^PHINQUESTION|83|260373001^Mutation Detected^SCT||||||FOBX|315|ST|LAB686^Molecular Susceptibility Nucleic Acid Change^PHINQUESTION|83|GAC>GTC||||||FOBX|316|ST|LAB687^Molecular Susceptibility Amino Acid Change^PHINQUESTION|83|Asp516Val||||||FOBX|317|CWE|LAB688^Molecular Susceptibility Indel^PHINQUESTION|83|UNK^Unknown^NULLFL||||||FOBX|318|CWE|LAB689^Molecular Susceptibility Test Method^PHINQUESTION|83|PHC1906^Nonsequencing^CDCPHINVS||||||FOBX|319|CWE|48018-6^Gene Identifier^LN|84|PHC1890^katG^CDCPHINVS||||||FOBX|320|TS|LAB682^Molecular Susceptibility Specimen Collection Date^PHINQUESTION|84|20170207||||||FOBX|321|TS|LAB683^Molecular Susceptibility Date Reported^PHINQUESTION|84|20170218||||||FOBX|322|CWE|LAB684^Molecular Susceptibility Specimen Type^PHINQUESTION|84|119334006^sputum^SCT||||||FOBX|323|CWE|LAB685^Molecular Susceptibility Test Result^PHINQUESTION|84|260373001^Mutation Detected^SCT||||||FOBX|324|ST|LAB686^Molecular Susceptibility Nucleic Acid Change^PHINQUESTION|84|AGC>ACC||||||FOBX|325|ST|LAB687^Molecular Susceptibility Amino Acid Change^PHINQUESTION|84|Ser315Thr||||||FOBX|326|CWE|LAB688^Molecular Susceptibility Indel^PHINQUESTION|84|UNK^Unknown^NULLFL||||||FOBX|327|CWE|LAB689^Molecular Susceptibility Test Method^PHINQUESTION|84|PHC1907^Sequencing^CDCPHINVS||||||FOBX|328|CWE|48018-6^Gene Identifier^LN|85|PHC1896^embB^CDCPHINVS||||||FOBX|329|TS|LAB682^Molecular Susceptibility Specimen Collection Date^PHINQUESTION|85|20170207||||||FOBX|330|TS|LAB683^Molecular Susceptibility Date Reported^PHINQUESTION|85|20170218||||||FOBX|331|CWE|LAB684^Molecular Susceptibility Specimen Type^PHINQUESTION|85|119334006^sputum^SCT||||||FOBX|332|CWE|LAB685^Molecular Susceptibility Test Result^PHINQUESTION|85|260373001^Mutation Detected^SCT||||||FOBX|333|ST|LAB686^Molecular Susceptibility Nucleic Acid Change^PHINQUESTION|85|TTC>TGC||||||FOBX|334|ST|LAB687^Molecular Susceptibility Amino Acid Change^PHINQUESTION|85|Phe398Cys||||||FOBX|335|CWE|LAB688^Molecular Susceptibility Indel^PHINQUESTION|85|UNK^Unknown^NULLFL||||||FOBX|336|CWE|LAB689^Molecular Susceptibility Test Method^PHINQUESTION|85|PHC1907^Sequencing^CDCPHINVS||||||FOBX|337|CWE|INV1149^Culture Conversion Documented^PHINQUESTION||N^No^HL70136||||||FOBX|338|DT|INV1150^Date of First Consistently Negative Culture^PHINQUESTION||20180410||||||FOBX|339|CWE|INV1151^Reason for Not Documenting Sputum Culture Conversion^PHINQUESTION||OTH^Other (Specify)^NULLFL^^^^^^Not originally documented||||||FOBX|340|CWE|TB279^Patient Move During TB Therapy^PHINQUESTION||Y^Yes^HL70136||||||FOBX|341|CWE|INV1152^Moved to Where^PHINQUESTION||PHC1911^Out of United States^CDCPHINVS||||||FOBX|342|CWE|INV1154^Out of Country Move^PHINQUESTION||AUS^AUSTRALIA^ISO3166_1||||||FOBX|343|CWE|INV1155^Transnational Referral^PHINQUESTION||Y^Yes^HL70136||||||FOBX|344|CWE|INV1156^History of Treatment^PHINQUESTION||Y^Yes^HL70136||||||FOBX|345|DT|INV1157^Date MDR Treatment Started^PHINQUESTION||20170605||||||FOBX|346|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|86|641^Amikacin^RXNORM||||||FOBX|347|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|86|266710000^Not Taken^SCT||||||FOBX|348|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|87|7833^Para-Aminesalicylicacid^RXNORM||||||FOBX|349|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|87|266710000^Not Taken^SCT||||||FOBX|350|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|88|1364504^Bedaquiline^RXNORM||||||FOBX|351|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|88|PHC2093^>=1 month^CDCPHINVS||||||FOBX|352|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|89|78903^Capreomycin^RXNORM||||||FOBX|353|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|89|PHC2093^>=1 month^CDCPHINVS||||||FOBX|354|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|90|2551^Ciprofloxacin^RXNORM||||||FOBX|355|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|90|266710000^Not Taken^SCT||||||FOBX|356|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|91|2592^Clofazimine^RXNORM||||||FOBX|357|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|91|266710000^Not Taken^SCT||||||FOBX|358|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|92|3007^Cycloserine^RXNORM||||||FOBX|359|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|92|266710000^Not Taken^SCT||||||FOBX|360|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|93|PHC1889^Delamanid^CDCPHINVS||||||FOBX|361|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|93|266710000^Not Taken^SCT||||||FOBX|362|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|94|4110^Ethambutol^RXNORM||||||FOBX|363|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|94|PHC1915^<1 month^CDCPHINVS||||||FOBX|364|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|95|4127^Ethionamide^RXNORM||||||FOBX|365|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|95|266710000^Not Taken^SCT||||||FOBX|366|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|96|6038^Isoniazid^RXNORM||||||FOBX|367|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|96|266710000^Not Taken^SCT||||||FOBX|368|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|97|6099^Kanamycin^RXNORM||||||FOBX|369|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|97|PHC2093^>=1 month^CDCPHINVS||||||FOBX|370|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|98|82122^Levofloxacin^RXNORM||||||FOBX|371|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|98|266710000^Not Taken^SCT||||||FOBX|372|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|99|190376^Linezolid^RXNORM||||||FOBX|373|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|99|266710000^Not Taken^SCT||||||FOBX|374|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|100|139462^Moxifloxacin^RXNORM||||||FOBX|375|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|100|266710000^Not Taken^SCT||||||FOBX|376|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|101|7623^Ofloxacin^RXNORM||||||FOBX|377|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|101|266710000^Not Taken^SCT||||||FOBX|378|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|102|OTH^Other (specify)^NULLFL||||||FOBX|379|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|102|266710000^Not Taken^SCT||||||FOBX|380|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|103|PHC1888^Other Quinolones^CDCPHINVS||||||FOBX|381|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|103|266710000^Not Taken^SCT||||||FOBX|382|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|104|8987^Pyrazinamide^RXNORM||||||FOBX|383|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|104|266710000^Not Taken^SCT||||||FOBX|384|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|105|55672^Rifabutin^RXNORM||||||FOBX|385|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|105|PHC2093^>=1 month^CDCPHINVS||||||FOBX|386|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|106|9384^Rifampin^RXNORM||||||FOBX|387|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|106|PHC2093^>=1 month^CDCPHINVS||||||FOBX|388|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|107|35617^Rifapentine^RXNORM||||||FOBX|389|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|107|266710000^Not Taken^SCT||||||FOBX|390|CWE|INV1158^Drug Used to Treat MDR TB^PHINQUESTION|108|10109^Streptomycin^RXNORM||||||FOBX|391|CWE|INV1159^Length of Time Drug Was Administered^PHINQUESTION|108|266710000^Not Taken^SCT||||||FOBX|392|DT|INV1160^Date Injectable Medication Stopped^PHINQUESTION||20171103||||||FOBX|393|CWE|INV1161^Surgery to Treat MDR TB^PHINQUESTION||Y^Yes^HL70136||||||FOBX|394|DT|INV1162^Surgery to Treat MDR TB Date^PHINQUESTION||20171025||||||FOBX|395|CWE|42563-7^Adverse Event Description^LN|109|36358004^Cardiac Abnormalities^SCT||||||FOBX|396|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|109|Y^Yes^HL70136||||||FOBX|397|CWE|INV1163^Adverse Event Manifestation Time^PHINQUESTION|109|PHC1918^End of Treatment^CDCPHINVS||||||FOBX|398|CWE|42563-7^Adverse Event Description^LN|110|35489007^Depression^SCT||||||FOBX|399|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|110|Y^Yes^HL70136||||||FOBX|400|CWE|INV1163^Adverse Event Manifestation Time^PHINQUESTION|110|PHC1917^During Treatment^CDCPHINVS||||||FOBX|401|CWE|42563-7^Adverse Event Description^LN|111|445053006^Vestibular Dysfunction^SCT||||||FOBX|402|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|111|N^No^HL70136||||||FOBX|403|CWE|42563-7^Adverse Event Description^LN|112|15188001^Hearing Loss^SCT||||||FOBX|404|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|112|N^No^HL70136||||||FOBX|405|CWE|42563-7^Adverse Event Description^LN|113|57676002^Arthralgia^SCT||||||FOBX|406|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|113|N^No^HL70136||||||FOBX|407|CWE|42563-7^Adverse Event Description^LN|114|68962001^Myalgia^SCT||||||FOBX|408|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|114|N^No^HL70136||||||FOBX|409|CWE|42563-7^Adverse Event Description^LN|115|OTH^Other (specify)^NULLFL||||||FOBX|410|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|115|N^No^HL70136||||||FOBX|411|CWE|42563-7^Adverse Event Description^LN|116|302226006^Peripheral Neuropathy^SCT||||||FOBX|412|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|116|N^No^HL70136||||||FOBX|413|CWE|42563-7^Adverse Event Description^LN|117|236423003^Renal Dysfunction^SCT||||||FOBX|414|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|117|N^No^HL70136||||||FOBX|415|CWE|42563-7^Adverse Event Description^LN|118|60862001^Tinnitus^SCT||||||FOBX|416|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|118|Y^Yes^HL70136||||||FOBX|417|CWE|INV1163^Adverse Event Manifestation Time^PHINQUESTION|118|PHC1919^Both^CDCPHINVS||||||FOBX|418|CWE|42563-7^Adverse Event Description^LN|119|197354009^Liver Toxicity^SCT||||||FOBX|419|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|119|N^No^HL70136||||||FOBX|420|CWE|42563-7^Adverse Event Description^LN|120|PHC1920^Vision Change/Loss^CDCPHINVS||||||FOBX|421|CWE|INV1164^Adverse Event Indicator^PHINQUESTION|120|N^No^HL70136||||||F